RSS   Newsletter   Contact   Advertise with us
Post Online Media

David J. King joins aTyr Pharma as SVP, research

aTyr PharmaaTyr Pharma announced that David J. King has joined the company as senior vice president, research.
Article continues below

READ MORE aTyr Pharma appoints SVP, product programs and planning

Dr. King's industry experience is highlighted by his tenures at Medarex, Inc. (acquired by Bristol-Myers Squibb in 2009) and Celltech Therapeutics Ltd. (acquired by UCB in 2004).

At Medarex, he led programs to identify therapeutic antibodies and played a key role in programs targeting novel biologics (including PD-1), and at Celltech, he directed the protein biochemistry and antibody engineering activities that led to the discovery and development of Cimzia.

After Medarex, Dr. King served as Chief Scientific Officer at AnaptysBio, Inc. where he led research that developed a novel technology for generating antibody therapeutics, which was successfully used to generate innovative clinical candidates for a number of pharmaceutical partnerships and for internal development.

Most recently, he served as Senior Vice President of Research at Tunitas Therapeutics, where he led the company's research and preclinical activities.

Dr. King received his B.S. from the University of Warwick and his Ph.D. from the University of Surrey, both in the United Kingdom, and was a Glaxo Group Research postdoctoral fellow.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy